Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced its financial results for the second quarter ended May 31, 2019.

Theratechnologies Inc. (TSX: TH) (Theratechnologies) announced today that it will issue its financial results for the second quarter ended May 31, 2019, on Thursday, July 11, 2019.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce the launch of two direct-to-consumer campaigns for TROGARZO® (ibalizumab-uiyk) for injection and EGRIFTA® (tesamorelin for injection), its FDA-approved products in the United States.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it will pursue the development of tesamorelin for the treatment of Non-alcoholic steatohepatitis (“NASH”) in people living with HIV.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce additional data from the recently completed study funded by the National Institutes of Health, led by Dr. Steve Grinspoon, and conducted at the Massachusetts General Hospital and Harvard Medical School and the National Institutes of Health.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) today announced that it requested and obtained from the European Medicines Agency (EMA) an additional month to address new questions received yesterday in regard to the establishment of a post-approval registry to gather long-term data on patients taking Trogarzo® (ibalizumab) in Europe.

Theratechnologies Inc. (Theratechnologies) (TSX: TH) is pleased to announce that positive results from in vivo and in vitro research, using its specific Sortilin receptor platform for the treatment of triple-negative breast cancer and ovarian cancer, were published on-line in two abstracts as part of the American Society of Clinical Oncology (“ASCO”) annual conference.

Theratechnologies Inc. (TSX: TH) today held its annual meeting of shareholders.